Calithera BioSciences - Enzyme Activators as Cancer Therapeutics

 

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player


Recent News:

Calithera Biosciences Presents Pharmacodynamic Data
on CB-839 at the 2014 American Association for Cancer
Research Annual Meeting

Calithera Biosciences to Present Data on CB-839 at the
American Association for Cancer Research Annual Meeting 2014

Calithera Biosciences Appoints William D. Waddill as CFO

Calithera Biosciences Presents Preclinical Data for CB-839 Activity and Glutaminase Inhibition in Solid and Hematologic Tumors

First patient dosed on CB-839

Calithera Biosciences Presents Data for CB-839 in Triple-Negative Breast Cancer Models at the 2013 San Antonio Breast Cancer Symposium

Calithera Biosciences Presents Preclinical Data for CB-839 at the 55th American Society of Hematology Annual Meeting

October 29, 2013 - Calithera Biosciences Secures $35 Million in Series D Financing

 

Calithera is a development stage pharmaceutical company committed to discovering and developing novel small molecule therapeutics for the treatment of cancer.


We are applying our scientific expertise to build a pipeline of unique anti- cancer drugs that selectively target metabolic and apoptotic pathways critical to tumor growth and survival.